Skip to main content
SpringerLink
Log in

Cicatrisation muqueuse endoscopique

Mucosal healing

  • Recommandations / Recommendations
  • Published:
Acta Endoscopica

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990;99:956–963.

    PubMed  CAS  Google Scholar 

  2. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Gut 1989;30:983–989.

    Article  PubMed  CAS  Google Scholar 

  3. Hebuterne X, Lemann M, Bouhnik Y, Dewit O, Dupas JL, Mross M, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn’s disease following treatment with certolizumab pegol. Gut 2012;62:201–208.

    Article  PubMed  Google Scholar 

  4. Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, et al. Development and validation of a new, Simplified Endoscopic Activity Score for Crohn’s Disease: the SES-CD. Gastrointest Endosc 2004;60:505–512.

    Article  PubMed  Google Scholar 

  5. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15–29.

    Article  PubMed  Google Scholar 

  6. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625–1629.

    Article  CAS  Google Scholar 

  7. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61:535–542.

    Article  PubMed  Google Scholar 

  8. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–786.

    Article  PubMed  Google Scholar 

  9. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422.

    Article  PubMed  Google Scholar 

  10. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.

    Article  PubMed  CAS  Google Scholar 

  11. Ferrante M, Drobne D, Vermeire S, Van Assche G, Coopmans T, Hoffman I, et al. Long-term outcome of infliximab in patients with ulcerative colitis. Gut 2010;59(Suppl III):A193.

    Google Scholar 

  12. Laharie D, Filippi J, Roblin X, Nancey S, Chevaux JB, Hebuterne X, et al. Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Gastroenterology 2012:S1934.

  13. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohn’s Colitis 2011;5:477–483.

    Article  Google Scholar 

  14. Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011;9:483–489.

    Article  PubMed  Google Scholar 

  15. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis 2009;15:1295–1301.

    Article  PubMed  Google Scholar 

  16. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63:433–442.

    Article  PubMed  Google Scholar 

  17. D’Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–667.

    Article  PubMed  Google Scholar 

  18. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138:463–468.

    Article  PubMed  Google Scholar 

  19. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–1395.

    Article  PubMed  CAS  Google Scholar 

  20. Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology 2012;142:1102–1111.

    Article  PubMed  CAS  Google Scholar 

  21. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40–46.

    Article  PubMed  Google Scholar 

  22. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162–169.

    Article  PubMed  CAS  Google Scholar 

  23. D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218–2224.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hépatogastroentérologie, hôpital Sainte-Musse, avenue Sainte-Claire-Deville, F-83056, Toulon cedex, France

    D. Bernardini

  2. Service d’hépatogastroentérologie, hôpital Haut-Lévêque, CHU de Bordeaux, F-33600, Pessac, France

    D. Laharie

Authors
  1. D. Bernardini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Laharie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Bernardini.

About this article

Cite this article

Bernardini, D., Laharie, D. Cicatrisation muqueuse endoscopique. Acta Endosc 43, 123–128 (2013). https://doi.org/10.1007/s10190-013-0315-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10190-013-0315-3

Search

Navigation